Dear Editor,
COVID-19 remains a global health threat due to the sequential emergence of novel variants with immune escape capabilities. The predominant circulating variant worldwide has evolved from the prototype, Alpha, Beta, Delta, into Omicron and its subvariants1,2, especially the newly emerged XBB descendant lineages. The most updated version of licensed bivalent vaccines contained mRNAs encoding the Spike (S) protein of both prototype and BA.4/5, while the inclusion of ancestral strain antigen was evidenced to induce immune imprinting and lead to reduced vaccine efficacy against the circulating XBB lineage3,4,5. Recently, WHO and FDA have recommended to remove the prototype strain antigen in future formulations of COVID-19 vaccine. However, the immunogenicity and protection of an updated monovalent mRNA vaccine in pre-immune populations remains unknown.
Previously, we have developed a monovalent mRNA vaccine (termed ARCoV) targeting the receptor binding domain (RBD) of prototype SARS-CoV-26. ABO1020 is an updated version of ARCoV, which encodes the RBD of Omicron BA.4/5. Compared with the circulating XBB.1 lineages and ARCoV, ABO1020 contained 9 and 17 amino acid substitutions, respectively (Fig. 1a). This BA.4/5 monovalent mRNA vaccine ABO1020 is now in the final stage of international, multicenter, phase 3 trials (ClinicalTrials.gov Identifier: NCT05636319).
Herein, to determine the neutralizing antibodies against BA.4/5 and XBB.1 variants, sera from a cohort of volunteers who have received two doses (28-day interval booster) of ABO1020 booster (15 ug) were collected. All these participants are healthy adults aged 18 years and older who have previously completed a full course of 2 or 3 doses of COVID-19 inactivated vaccine (Supplementary Table S1). Similar to previous findings7, ABO1020 was safe and well tolerated, and no serious adverse events occurred after the 1st or 2nd booster. The neutralizing antibodies against BA.5 and XBB were determined by authentic virus assay as previously described8. The protocol and informed consent were approved by Ministry of Health and Prevention Research Ethics Committee of AL Kuwait Hospital (MOHAP/DXB-REC/SOO/No.80/2022). This study was conducted in accordance with the principles of the Declaration of Helsinki and Good Clinical Practice.
As expected, all subjects (n = 19) produced high levels of BA.5 neutralizing antibodies on day 28 after the 1st booster with ABO1020, and the geometric mean titer (GMT) of neutralizing antibodies reached 3554, with the neutralizing geometric mean fold increase (GMFI) of 12.3 than before booster. On day 28 after the second booster, the neutralizing antibodies against BA.5 further increased to 4915 (GMFI 17.1). Most importantly, the neutralizing antibodies titers against XBB reached 257 (GMFI 7.7) and 589 (GMFI 17.7) after 1st and 2nd booster, respectively (Fig. 1b). Remarkably, the seropositivity rate against XBB increased from 73.7% to 94.7% after the first booster, respectively (Supplementary Fig. S1a).
As the 2nd booster with ABO1020 failed to significantly increase the neutralizing antibody titers against either BA.5 or XBB (Fig. 1b; Supplementary Fig. S2a), we further assayed the impact of a single booster with ABO1020 with another cohort of volunteers (n = 13) (Supplementary Table S2). Similar to above results, a single booster with ABO1020 induced high level of neutralizing antibodies against BA.5 (GMT 651, GMFI 7.4) as well as XBB.1.9 (GMT 206, GMFI 17.0) 14 days post booster (Fig. 1c; Supplementary Fig. S2b). Meanwhile, the seropositivity rate of XBB.1.9 increased from 69.2 to 100% (Supplementary Fig. S1b).
Finally, the neutralizing antibody titers against prototype, Delta and Omicron subvariants (BA.1, BA.2.12.1, BA.2.75.2, BA.4/5, BF.7, XBB.1.5, XBB.1.16, BQ.1.1) were detected by pseudovirus neutralization assay in one dose group (Supplementary Table S3). As shown in Fig. 1d and Supplementary Fig. S3, a single booster with ABO1020 could readily induce production of neutralizing antibodies against all tested variants. Especially, the neutralizing antibody titers against XBB.1.5 increased by the highest fold (GMFI 38.9), followed by those against BA.2.75.2 and BA.4/5 (GMFI 23.3 and 18.8, respectively), while the antibody titers against the original strain only increased by 3.50 times. Together, all these results demonstrate that a single- or two-dose booster of ABO1020 induced broad and potent neutralizing antibodies against multiple variants including the XBB.1 variants, with reduced induction of immune imprinting.
The immunogenicity of bivalent mRNA vaccines has been well documented in different populations, while they failed to neutralize XBB subvariants, including XBB.1 and XBB.1.1, with peak titers against the prototype strain4,9,10. Our present study confirmed that a single booster with a BA.4/5 monovalent mRNA vaccine in different populations was sufficient to induce protective antibodies against the circulating strains including XBB.1 lineage. Although the population size is limited, all participants at different immune or infection statues showed 100% seroconversion, and the high neutralizing antibodies from authentic virus assay would probably confer significant protection against the circulating XBB.1 variant. As a monovalent vaccine targeting XBB is not available in a short time, the use of a monovalent BA.4/5 mRNA vaccine provides an accessible strategy in response to the ongoing COVID-19 pandemic. Whether other monovalent BA.4/5 mRNA vaccines targeting the full S protein have similar effects deserves immediate investigation.
References
Callaway, E. Nature 611, 213–214 (2022).
Carabelli, A. M. et al. Nat. Rev. Microbiol. 21, 162–177 (2023).
Cao, Y. et al. Nature 614, 521–529 (2023).
Wang, Q. et al. Cell 186, 279–286 (2023).
Röltgen, K. et al. Cell 185, 1025–1040 (2022).
Zhang, N. N. et al. Cell 182, 1271–1283 (2020).
Hannawi, S. et al. Clin. Transl. Med. 13, e1387 (2023).
Wang, Z. et al. Emerg. Microbes Infect. 11, 829–840 (2022).
Zou, J. et al. N. Engl. J. Med. 388, 854–857 (2023).
Miller, J. et al. N. Engl. J. Med. 388, 662–664 (2023).
Acknowledgements
We thank all participants in this study. We thank Min Gao, Kai Li, Xun Huang and Chao Zhou for sample collection and data analysis. This work was supported by the National Key R&D Project of China (2021YFC2302400 and 2021YFC0865800), the National Natural Science Foundation China (92169120), and Guangdong Basic and Applied Research Projects (2021B1212030016 J.D. and 2021A1111100009 J.D.). C.F.Q. was supported by the National Science Fund for Distinguished Young Scholars (81925025), the Innovative Research Group (81621005) from the NSFC, and the Innovation Fund for Medical Sciences (2019-I2M-5-049) from the Chinese Academy of Medical Sciences.
Author information
Authors and Affiliations
Contributions
C.F.Q. and H.Z. conceived and supervised the study. H.Z., N.N.Z., S.H., and A.R.Z. designed and coordinated the experiments. X.C.X., C.J.C., and A.A. performed experiments. H.Z. and N.N.Z. analyzed the data. Y.J.H., D.D.Y., J.D., B.Y., and J.C.Z. helped in the sample collection and organization. C.F.Q., H.Z., and N.N.Z. drafted and revised the manuscript. All authors reviewed and approved the final manuscript.
Corresponding authors
Ethics declarations
Conflict of interest
C.F.Q. and B.Y. are co-inventors of the COVID-19 mRNA vaccine. D.D.Y. and B.Y. are employees of Suzhou Abogen Biosciences. All other authors declare no competing interests.
Additional information
Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Supplementary information
Rights and permissions
Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.
About this article
Cite this article
Zhao, H., Zhang, NN., Hannawi, S. et al. Neutralization of Omicron XBB.1 by booster vaccination with BA.4/5 monovalent mRNA vaccine. Cell Discov 10, 7 (2024). https://doi.org/10.1038/s41421-023-00609-0
Received:
Accepted:
Published:
DOI: https://doi.org/10.1038/s41421-023-00609-0